Germline mutations determining increased cutaneous malignant melanoma (CMM) risk have been identified in familial and sporadic CMM cases, but they account only for a small proportion of CMM cases. Recent evidence suggests that germline epimutations (e.g. DNA methylation alterations), which can be inherited similarly to genomic mutations and can be detected in normal body cells (including blood), might increase susceptibility to cancer. The aim of the study was to identify germline epimutations of genes that were found to be mutated in familial CMM (p16 INK4a , p14 ARF , CDK4, MC1R, hTERT), immune and inflammatory genes (ICAM-1, TNFα), DNA mismatch repair gene (MLH1), and repetitive elements (ALU, LINE-1, HERV-w).
Introduction
The overall worldwide incidence of cutaneous malignant melanoma (CMM) is increasing faster than that of any other cancer [1] . Current estimates indicate that the incidences of CMM will double over the next 20 years in most white populations [2] . Late-stage CMM is highly fatal. Once diagnosed with metastatic CMM, most patients die of their disease within 2 years [3] . Approximately 10-13% of CMM cases are clustered in families, whereas the remaining are diagnosed as sporadic CMM [4] . Germline mutations have been identified in both familiar and sporadic CMMs [5] . However, even mutations of p16 INK4a , the most common of the germline mutations in CMM, have been detected in ∼ 20-40% of melanoma-prone families (reviewed in Hill et al. [6] ) and in 0.2-3% of sporadic CMM cases of Northern European descent [6] [7] [8] . Other genetic determinants associated with CMMfor example, germline mutations of p14 ARF and CDK4, and variants in melanocortin 1 receptor (MC1R, associated with fair pigmentation), telomerase reverse transcriptase (hTERT), microphthalmiaassociated transcription factor (MITF), and BAP1taken together account for an even lower proportion of CMM-attributable risk [9] [10] [11] [12] [13] [14] .
Epimutations, because of increased DNA methylation, are very common somatic events, and can also arise in the germline and cause soma-wide transcriptional silencing of a gene [15] . Somatic epimutations are restricted to the tumor tissue and precursor lesions. Recent evidence suggests that germline epimutations, which can be inherited similarly to what happens for genomic mutations and can thus be detected in normal body cells (including peripheral blood), might increase cancer susceptibility [16] [17] [18] [19] .
We therefore hypothesize that alterations in blood DNA methylation of specific genes, which have been linked to heritable traits that are not related to differences in the All supplementary digital content is available directly from the corresponding author.
DNA sequence [20, 21] , might contribute toward determining the risk of CMM unaccounted for by genetic mutations.
To test this hypothesis, we measured DNA methylation of the same genes that were found to be mutated in familial CMM (p16 INK4a , p14 ARF , CDK4, MC1R, hTERT) in 167 sporadic CMM cases and 164 frequency-matched controls, investigated previously for genetic mutations [22] . Moreover, we investigated two genes known to impact immune and inflammatory response (ICAM-1 and TNFα) [23] as CMM is considered a representative model for cross-talk between immune responses and malignancy [24] ; a DNA mismatch repair gene (hMLH1), representing the first example of germline epimutation in cancer [16, 25] ; and three repetitive elements (ALU, LINE-1, HERV-w), as reduced levels of repetitive elements methylation in blood have been associated with genomic instability and cancer risk [26] .
Participants and methods

Study participants
This study has been described previously [21, 22] . In brief, 183 cases of CMM were recruited between 1994 and 1996 at the Dermatology Department of the Maurizio Bufalini Hospital of Cesena, Italy. The 179 sexmatched and age-matched control participants were living in the same geographic area and included 134 spouses or close friends of the CMM patients, 14 outpatients referred to the hospital because of minor accidental trauma, and 31 healthy volunteers from among hospital personnel.
All study participants underwent a full body skin examination performed by a single dermatologist to characterize phenotypes (pigmentation characteristics, freckling, type and total number of nevi, presence of skin lesions, and presence of other skin cancers), completed a standardized in-person questionnaire, assisted by trained interviewers, and donated a blood sample collected in heparin tubes. DNA was available for 167 CMM cases and 164 controls. The diagnosis of dysplastic nevi, defined as number of common melanocytic nevi on the back of participants, was confirmed on standardized photographs by an expert oncologist blinded to CMM status. To be defined as dysplastic, a nevus had to be 5 mm or larger, had to be predominantly flat, and had to have at least two of the following criteria: variable pigmentation, indistinct borders, and irregular outline [27] .
DNA extraction and bisulfite treatment
Genomic DNA was extracted from peripheral blood mononuclear cells (PBMCs), using the Nucleon Extraction and Purification Kit (Amersham Biosciences, Uppsala, Sweden), following the manufacturer's instructions.
A measure of 500 ng DNA (concentration 50 ng/μl) was treated using EZ DNA Methylation-Gold Kit (Zymo Research, Orange, California, USA) according to the manufacturer's protocol. Final elution was performed with 30 μl of M-Elution Buffer (Zymo Research).
DNA methylation analysis
Analysis of DNA methylation was carried out using previously published methods [28, 29] , with minor modifications. Briefly, a 50 μl PCR was carried out in 25 μl of GoTaq Green Master Mix (Promega, Madison, Wisconsin, USA), 1 pmol of the forward primer, 1 pmol of the biotinylated reverse primer, 50 ng of bisulfite-treated genomic DNA, and water. PCR cycling conditions and primer sequences are reported in Table 1 . The biotinlabeled primers were used to purify the final PCR product using Sepharose beads. The PCR product was bound to Streptavidin Sepharose HP (Amersham Biosciences) and the Sepharose beads containing the immobilized PCR product were purified, washed, denatured using a 0.2 mol/l NaOH solution, and washed again using the Pyrosequencing Vacuum Prep Tool (Pyrosequencing Inc., Westborough, Massachusetts, USA), as recommended by the manufacturer. Then, 0.3 μmol/l pyrosequencing primer was annealed to the purified single-stranded PCR product and pyrosequencing was performed using the PyroMark MD System (Pyrosequencing Inc.). The degree of methylation was expressed as percentage of methylated cytosines divided by the sum of methylated and unmethylated cytosines (%5mC). Every sample was tested three times for each marker to confirm reproducibility and increase the precision of our results. The average of the three replicates was used in statistical analyses.
Statistical analysis
Phenotypic characteristics of cases and controls were compared using the χ 2 -test or Fisher's exact test for categorical variables and for continuous variables by the Wilcoxon rank-sum test.
We computed odds ratios (ORs) and 95% confidence intervals (CIs) for the association of methylation levels with case/control status using multivariable logistic regression models. To reduce the number of adjustment variables and to account for correlations between the pigmentation characteristics of an individual, we used factor analysis with varimax rotation among those individuals who did not have missing values on eye color, hair color, skin type, nevi number, and presence of dysplastic nevi. Factor analysis identified two factors: factor 1 (pigmentation factor), corresponding to pigmentation characteristics including eye color, hair color, and skin type, and factor 2 (nevi factor), represented by number of nevi and the presence of dysplastic nevi. The interaction between nevi number, presence of dysplastic nevi, pigmentation factor, nevi factor, and DNA methylation was assessed in multivariable logistic models. All analyses were repeated stratified by the number of nevi (≤ 20, > 20), adjusted for age, sex, and pigmentation factor.
Among the controls, we used linear regression models to assess the association of participants' characteristics with methylation levels. We also computed ORs and 95% CIs for the association of the presence of dysplastic nevi and DNA methylation levels using logistic regression models adjusting for age and sex. We further adjusted the OR for the 'pigmentation factor'. Statistical analysis was carried out using SAS software (version 9.2; SAS Institute, Milan, Italy). A two-sided P-value of less than 0.05 was considered statistically significant.
Results
Study population
As expected, pigmentation characteristics were significantly different between cases and controls [hair, eye and skin color, presence of freckles, tanning ability to prolonged sun exposure, presence of dysplastic nevi (DN), and number of nevi] ( Supplementary Table 1 ).
Moreover, cases had lower methylation levels than controls in the CDK4 gene (mean cases = 2.24%, mean controls = 2.72%; P = 0.0076) and in MLH1 gene (mean cases = 11.0%, mean controls = 10.25%; P = 0.01) ( Table 2 ). Supplementary Table 2 .
Melanoma characteristics of the cases are presented in
DNA methylation and dysplastic nevi risk in controls
We explored associations between gene-specific methylation levels and participants' characteristics and found several suggestive associations (Table 3 ).
In a logistic regression model adjusted for age and sex, there was a suggestive negative association between DN risk and hypermethylation of hTERT (OR = 0.90, 95% CI = 0.82-0.99) and TNFα (OR = 0.81, 95% CI = 0.69-0.95) ( Table 4 ). In contrast, hypermethylation of ALU was associated with an increased risk of DN (OR = 1.56, 95% CI = 1.02-2.39).
This pattern persisted when pigmentation factor was added to the regression model, for hTERT (OR = 0.91, 95% CI = 0.84-1.00), TNFα (OR = 0.82, 95% CI = 0.70-0.96), and ALU (OR = 1.51, 95% CI = 1.00-2.28). We did not include nevi factor in the model as it included the presence of DN and nevus count.
DNA methylation and cutaneous malignant melanoma risk
In logistic regression analyses adjusted for age and sex, the risk of CMM was associated positively with methylation levels of the p16 INK4a gene (OR = 1.28, 95% CI = 1.03-1.59) and the MLH1 gene (OR = 1.14, 95% CI = 1.01-1.27) ( Table 5 ). When we adjusted additionally for the pigmentation and nevi factors, the OR for p16 INK4a methylation was no longer significant (OR = 1.14, 95% CI = 0.97-1.34), whereas the risk of CMM was associated positively with methylation of the TNFα gene (OR = 1.11, 95% CI = 1.03-1.18) and MLH1 (OR = 1.12, 95% CI = 1.02-1.22) and associated negatively with CDK4 (OR = 0.76, 95% CI = 0.64-0.91).
We observed a different pattern of methylation when we stratified analyses by nevi number (Table 6 ). Among individuals with less than 20 nevi, we found a positive association between methylation of ICAM-1 (OR = 2.45, 95% CI = 1.01-5.94), TNFα (OR = 1.49, 95% CI = 1.17-1.90), and ALU (OR = 2.37, 95% CI = 1.13-4.95), and the risk of CMM (Table 6 ). In contrast, among participants with more than 20 nevi, we found an association of CMM risk with methylation of CDK4 (OR = 0.57, 95% CI = 0.42-0.77) and MLH1 (OR = 1.29, 95% CI = 1.12-1.50) ( Table 6 ). The interaction term between the number of nevi and DNA methylation was significant in the logistic model for ICAM-1 (P = 0.02), TNFα (P < 0.01), ALU (P < 0.01), LINE-1 (P = 0.02), CDK4 (P < 0.01), and MLH1 (P = 0.02) ( Table 6 ).
For the sensitivity analysis, we also stratified the number of nevi variables as above and below the median (number of nevi =34), obtaining similar results (data not shown).
Discussion
In a case-control study of CMM from Italy, we found an association between methylation levels in blood DNA of TNFα, CDK4 and MLH1, and the risk of CMM. Moreover, methylation levels of TNFα, hTERT, and ALU were associated with the risk of developing dysplastic nevi in the control participants. For the first time, we found that methylation of specific genes, detectable in surrogate tissues such as PBMCs, could be involved in the development of CMM.
Epimutations occurring in a germline cell are believed to be maintained throughout development; thus, all somatic cells originating from the germline would carry these epimutations. Methylation alterations have been observed frequently in nontumor surrogate tissue, such as leukocytes and buccal cells, of cancer patients, suggesting that DNA methylation changes in cancer may be systemic and detectable in peripheral blood (surrogate tissue) (reviewed in [30] ).
Therefore, what we observed in peripheral blood samples may reflect the environment in the melanocytes, and could have an impact on the development of melanocyterelated traits (such as nevi or dysplastic nevi) and diseases (such as CMM).
CMM tissue methylation has been evaluated recently using a genome-wide approach, which showed that melanoma is characterized by a diffuse epigenetic deregulation, with many genes showing tumor-selective aberrant methylation [31] . In this study, highly recurrent methylation of the HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C, and CLDN11 genes was established. This evidence follows a previous study, showing genomic loss of 5-hydroxymethylcytosine in CMM [32] .
The changes observed in CMM tissue, however, might be the result of processes that occur later in the pathogenesis of cancer, given the complex modification occurring in the fully developed cancer phenotype.
DNA methylation in peripheral blood has been investigated previously in one single study, which evaluated LINE-1 methylation in CMM-prone families. This study, however, found no significant evidence that changes in global LINE-1 methylation in peripheral blood were associated with familial CMM risk [33] . This negative result was also confirmed in our study. Alterations in DNA methylation, in particular in LINE-1 elements, have also been reported to be independent prognostic factors in melanoma patients. Methylation as a prognostic marker might help in achieving a more appropriate clinical management of cutaneous melanoma [34] .
We surmise that DNA hypermethylation (i.e. epimutations) in the loci that harbor the known CMM-related genetic variations might determine the risk of CMM. Because these loci have functions that have been shown to be causally associated with the risk of CMM, they represent prime candidates for CMM epimutations.
Among the genes whose methylation levels were associated with CMM, the MLH1 may play an important role. MHL1 is a major mismatch repair gene involved in maintaining the stability of the genome [16] . Germline hypermethylation of MLH1 has been found in peripheral tissues (including PBMCs) of colon cancer families with no MLH1 genetic mutations [16, 25] , emphasizing the role of this gene in epimutation-related phenotypes. This mechanism might be generalized to different kinds of Table 3 Slope coefficients from linear regression models evaluating the association between DNA methylation and control participants' characteristics cancer, including CMM. If confirmed, MLH1 epimutation analysis could provide a tool for CMM risk stratification.
Another gene found to be associated with the risk of CMM was CDK4, one of the two major high-penetrance susceptibility genes associated with familial CMM [12] . CDK4, in conjunction with the D-type cyclins, mediates progression through the G1 phase when the cell prepares to initiate DNA synthesis. Activating mutations in this gene result in a predisposition of individuals to the development of CMM [35, 36] . Hypomethylation of this gene, resulting in increased CDK4 expression, might induce uncontrolled proliferation and might have a functional effect similar to the one exerted from CDK4 mutation on the risk of CMM.
TNFα was also associated with the risk of CMM. TNFα is a proinflammatory cytokine that has been shown to play an important role in tumorigenesis [37] , tumor progression [38] , and tumor invasiveness [39] . TNFα may also favor the formation of a permissive microenvironment for tumor invasion [40] . A direct association between the development of cancer and inflammation has long been appreciated. On the one hand, there is evidence to suggest that the inflammatory and immune systems may inhibit the development of cancer; on the other, longstanding inflammation secondary to chronic infection or irritation predisposes to cancer [41] . We found that participants carrying dysplastic nevi tended to have lower methylation levels of TNFα, whereas CMM cases were associated with increased TNFα promoter methylation. It is possible that the TNFα-related proinflammatory environment contributes toward the stability of the dysplastic nevi which are strong risk factors for melanoma but rarely progress to CMM [42] . Conversely, increased methylation levels and related decreased expression of TNFα may confer a lower protection toward development of CMM. This is just speculative at this point and needs to be further explored in a larger population.
We found a protective role against DN for hTERT (human telomerase catalytic subunit) hypermethylation. The major role of telomerase is to catalyze the de novo addition of telomeric repeat sequences onto chromosome ends and thereby to counterbalance telomere-dependent replicative aging. Two prospective studies have reported that shorter telomeres measured in peripheral blood were associated with a decreased risk of CMM [10, 43, 44] . Moreover, two independent studies identified, with high frequency, mutations within the core promoter of hTERT [45, 46] . Although the cancer genome is characterized by many recurrent mutations in the protein-coding regions of genes, regulatory regions are rarely mutated. In CMM, somatic mutations in regulatory regions of the genome may then represent an important tumorigenic mechanism. Similarly, hypermethylation of the hTERT promoter might play a critical role in the negative regulation of telomerase activity in normal human cells, thus limiting the DN growth.
The identification of alterations in peripheral blood DNA methylation, possibly linked to an increased risk of developing CMM, might be suggestive of a new mechanism able to explain CMM onset in those patients who do not carry known genetic alterations. We also observed an interaction between the number of nevi and methylation levels of specific genes in association with the risk of CMM. In particular, genes involved in inflammatory pathways, such as ICAM-1 [47] or TNFα, were associated with the risk of CMM in participants with low number of nevi, whereas methylation levels in susceptibility genes for CMM, such as CDKN2A [6] or CDK4, were associated more strongly with the risk of CMM in participants carrying many nevi. Although based on a small number of participants, these findings are suggestive of at least two distinct pathways for the development of CMM. One, for participants with 'many' nevi, which may involve CMM susceptibility genes such as p16 INK4a and CDK4, through either genetic or epigenetic regulation, and the other for participants with fair pigmentation and consequent oxidative stress, which may involve genes in inflammation or DNA repair pathways.
The results we presented in this paper suggest that methylation levels of specific loci may have an impact on the risk of CMM. However, because methylation levels in peripheral blood have been shown to be altered by several factors, including diet, environmental exposure, and lifestyle habits [48] , we cannot exclude the possibility that the changes observed might be because of other confounding factors.
An important limitation of this study is that, because of the case-control design, we could not exclude that the aberrant DNA methylation we detected in blood is a consequence, rather than a cause, of the fully developed CMM. Given the early stage of the disease in our cases, it is, however, unlikely that the tumors could have strongly altered methylation levels in blood. Moreover, this limitation does not apply to our findings in control participants related to the development of dysplastic nevi.
In conclusion, we found that epimutations in CMM susceptibility genes and in genes involved in response to oxidative damage are associated with the risk of developing CMM or dysplastic nevi. Further study measuring methylation levels of these genes in large prospective studies is warranted to further elucidate their role in the development and progression of CMM.
